138330-18-4,MFCD00867012
Catalog No.:AA0018HP

138330-18-4 | Phosphonic acid, P,P'-[(cycloheptylamino)methylene]bis-, sodium salt (1:2)

Pack Size
Purity
Availability
Price(USD)
Quantity
  
25mg
≥98%
2 weeks  
$286.00   $200.00
- +
100mg
≥98%
2 weeks  
$534.00   $374.00
- +
250mg
≥98%
2 weeks  
$971.00   $680.00
- +
  • Technical Information
  • Properties
  • Literature
  • Request for Quotation
  • Download SDS
Technical Information
Catalog Number:
AA0018HP
Chemical Name:
Phosphonic acid, P,P'-[(cycloheptylamino)methylene]bis-, sodium salt (1:2)
CAS Number:
138330-18-4
Molecular Formula:
C8H17NNa2O6P2
Molecular Weight:
331.1507
MDL Number:
MFCD00867012
SMILES:
[O-]P(=O)(C(P(=O)(O)O)NC1CCCCCC1)[O-].[Na+].[Na+]
Properties
Computed Properties
 
Complexity:
302  
Covalently-Bonded Unit Count:
3  
Defined Atom Stereocenter Count:
0  
Defined Bond Stereocenter Count:
0  
Formal Charge:
0  
Heavy Atom Count:
19  
Hydrogen Bond Acceptor Count:
7  
Hydrogen Bond Donor Count:
3  
Isotope Atom Count:
0  
Rotatable Bond Count:
4  
Undefined Atom Stereocenter Count:
0  
Undefined Bond Stereocenter Count:
0  

Literature

Title: The bisphosphonate incadronate inhibits intraperitoneal dissemination in an in vivo pancreatic cancer model.

Journal: Oncology reports 20120701

Title: [Long-term and high-dose bisphosphonate administration causes no bone over-mineralization].

Journal: Zhonghua yi xue za zhi 20091117

Title: Ibadronate may prevent colorectal carcinogenesis in mice with ulcerative colitis.

Journal: Anticancer research 20091101

Title: Collagen maturity, glycation induced-pentosidine, and mineralization are increased following 3-year treatment with incadronate in dogs.

Journal: Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20080901

Title: Lung and bone metastases from renal cell carcinoma responsive to bisphosphonates: a case report.

Journal: International journal of urology : official journal of the Japanese Urological Association 20080601

Title: Sugar synthesis from a gas-phase formose reaction.

Journal: Astrobiology 20070601

Title: Bisphosphonate incadronate inhibits growth of human T-cell leukaemia virus type I-infected T-cell lines and primary adult T-cell leukaemia cells by interfering with the mevalonate pathway.

Journal: British journal of haematology 20070201

Title: Inhibition of bone resorption in cultures of mouse calvariae by apicularen A.

Journal: Planta medica 20070201

Title: Incadronate induces cell detachment and apoptosis in prostatic PC-3 cells.

Journal: Anticancer research 20070101

Title: Hyperbaric oxygen in addition to antibiotic therapy is effective for bisphosphonate-induced osteonecrosis of the jaw in a patient with multiple myeloma.

Journal: International journal of hematology 20061101

Title: Incadronate inhibits aminopeptidase N expression in prostatic PC-3 cells.

Journal: Cancer letters 20060618

Title: Inhibition of caveolin-1 expression by incadronate in PC-3 prostate cells.

Journal: Anticancer research 20060101

Title: Effect of incadronate on proliferation of mesenchymal tumor cells with or without activated Ras mutation.

Journal: Journal of experimental & clinical cancer research : CR 20051201

Title: Nitrogen-containing bisphosphonate incadronate augments the inhibitory effect of farnesyl transferase inhibitor tipifarnib on the growth of fresh and cloned myeloma cells in vitro.

Journal: Leukemia & lymphoma 20051101

Title: Combination therapy with thalidomide, incadronate, and dexamethasone for relapsed or refractory multiple myeloma.

Journal: International journal of hematology 20051001

Title: Incadronate disodium inhibits joint destruction and periarticular bone loss only in the early phase of rat adjuvant-induced arthritis.

Journal: Journal of bone and mineral metabolism 20050101

Title: Effect of incadronate on corticosteroid-induced osteopenia in rats.

Journal: Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan 20040901

Title: Alendronate inhibits urinary calcium microlith formation in a three-dimensional culture model.

Journal: Urological research 20040601

Title: Nitrogen-containing bisphosphonates induce S-phase cell cycle arrest and apoptosis of myeloma cells by activating MAPK pathway and inhibiting mevalonate pathway.

Journal: Cellular signalling 20030701

Title: Antiinflammatory and chondroprotective effects of the aminobisphosphonate incadronate (YM175) in adjuvant induced arthritis.

Journal: The Journal of rheumatology 20030601

Title: [Changes of urinary deoxypyridinoline crosslink/creatinine in rats after ovariectomy and anti-osteoporotic intervention].

Journal: Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae 20030601

Title: Incadronate amplifies prostaglandin F2 alpha-induced vascular endothelial growth factor synthesis in osteoblasts. Enhancement of MAPK activity.

Journal: The Journal of biological chemistry 20030523

Title: Hydronium (cycloheptylammonio)methylene-1,1-bisphosphonate (hydronium incadronate).

Journal: Acta crystallographica. Section C, Crystal structure communications 20030201

Title: Bisphosphonate therapy for hormone refractory prostate cancer with bone metastasis.

Journal: The Journal of urology 20030101

Title: Effects of bisphosphonate on bone reaction after placement of titanium implants in tibiae of ovariectomized rats.

Journal: The International journal of oral & maxillofacial implants 20030101

Title: Incadronate disodium inhibits advanced glycation end products-induced angiogenesis in vitro.

Journal: Biochemical and biophysical research communications 20020920

Title: Comparison of incadronate and alfacalcidol on increased bone turnover caused by ovariectomy in rats.

Journal: European journal of pharmacology 20020802

Title: Incadronate and etidronate accelerate phosphate-primed mineralization of MC4 cells via ERK1/2-Cbfa1 signaling pathway in a Ras-independent manner: further involvement of mevalonate-pathway blockade for incadronate.

Journal: Japanese journal of pharmacology 20010501

Title: Long-term effect of incadronate disodium (YM-175) on fracture healing of femoral shaft in growing rats.

Journal: Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20010301

Title: A newly developed bisphosphonate, YM529, is a potent apoptosis inducer of human myeloma cells.

Journal: Leukemia research 20010101

Title: [A case of effective bisphosphonate therapy of sequential pamidronate and incadronate for bone metastases from breast cancer].

Journal: Gan to kagaku ryoho. Cancer & chemotherapy 20000801

Title: The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway.

Journal: Cancer research 19981201

Title: Pharmacokinetics of incadronate, a new bisphosphonate, in healthy volunteers and patients with malignancy-associated hypercalcemia.

Journal: International journal of clinical pharmacology and therapeutics 19970601

Quotation Request
Company Name:
*
Contact Person:
*
Email:
*
Quantity Required:
*
Country:
Additional Info:
SDS
Related Products of 138330-18-4
Tags:138330-18-4 Molecular Formula|138330-18-4 MDL|138330-18-4 SMILES|138330-18-4 Phosphonic acid, P,P'-[(cycloheptylamino)methylene]bis-, sodium salt (1:2)
Catalog No.: AA0018HP
138330-18-4,MFCD00867012
138330-18-4 | Phosphonic acid, P,P'-[(cycloheptylamino)methylene]bis-, sodium salt (1:2)
Pack Size: 25mg
Purity: ≥98%
2 weeks
$286.00 $200.00
Pack Size: 100mg
Purity: ≥98%
2 weeks
$534.00 $374.00
Pack Size: 250mg
Purity: ≥98%
2 weeks
$971.00 $680.00
Quantity
- +
Add to Card
Order Now
bulk Quotation Request
Technical Information
Catalog Number: AA0018HP
Chemical Name: Phosphonic acid, P,P'-[(cycloheptylamino)methylene]bis-, sodium salt (1:2)
CAS Number: 138330-18-4
Molecular Formula: C8H17NNa2O6P2
Molecular Weight: 331.1507
MDL Number: MFCD00867012
SMILES: [O-]P(=O)(C(P(=O)(O)O)NC1CCCCCC1)[O-].[Na+].[Na+]
Properties
Complexity: 302  
Covalently-Bonded Unit Count: 3  
Defined Atom Stereocenter Count: 0  
Defined Bond Stereocenter Count: 0  
Formal Charge: 0  
Heavy Atom Count: 19  
Hydrogen Bond Acceptor Count: 7  
Hydrogen Bond Donor Count: 3  
Isotope Atom Count: 0  
Rotatable Bond Count: 4  
Undefined Atom Stereocenter Count: 0  
Undefined Bond Stereocenter Count: 0  
Literature fold

Title: The bisphosphonate incadronate inhibits intraperitoneal dissemination in an in vivo pancreatic cancer model.

Journal: Oncology reports20120701

Title: [Long-term and high-dose bisphosphonate administration causes no bone over-mineralization].

Journal: Zhonghua yi xue za zhi20091117

Title: Ibadronate may prevent colorectal carcinogenesis in mice with ulcerative colitis.

Journal: Anticancer research20091101

Title: Collagen maturity, glycation induced-pentosidine, and mineralization are increased following 3-year treatment with incadronate in dogs.

Journal: Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA20080901

Title: Lung and bone metastases from renal cell carcinoma responsive to bisphosphonates: a case report.

Journal: International journal of urology : official journal of the Japanese Urological Association20080601

Title: Sugar synthesis from a gas-phase formose reaction.

Journal: Astrobiology20070601

Title: Bisphosphonate incadronate inhibits growth of human T-cell leukaemia virus type I-infected T-cell lines and primary adult T-cell leukaemia cells by interfering with the mevalonate pathway.

Journal: British journal of haematology20070201

Title: Inhibition of bone resorption in cultures of mouse calvariae by apicularen A.

Journal: Planta medica20070201

Title: Incadronate induces cell detachment and apoptosis in prostatic PC-3 cells.

Journal: Anticancer research20070101

Title: Hyperbaric oxygen in addition to antibiotic therapy is effective for bisphosphonate-induced osteonecrosis of the jaw in a patient with multiple myeloma.

Journal: International journal of hematology20061101

Title: Incadronate inhibits aminopeptidase N expression in prostatic PC-3 cells.

Journal: Cancer letters20060618

Title: Inhibition of caveolin-1 expression by incadronate in PC-3 prostate cells.

Journal: Anticancer research20060101

Title: Effect of incadronate on proliferation of mesenchymal tumor cells with or without activated Ras mutation.

Journal: Journal of experimental & clinical cancer research : CR20051201

Title: Nitrogen-containing bisphosphonate incadronate augments the inhibitory effect of farnesyl transferase inhibitor tipifarnib on the growth of fresh and cloned myeloma cells in vitro.

Journal: Leukemia & lymphoma20051101

Title: Combination therapy with thalidomide, incadronate, and dexamethasone for relapsed or refractory multiple myeloma.

Journal: International journal of hematology20051001

Title: Incadronate disodium inhibits joint destruction and periarticular bone loss only in the early phase of rat adjuvant-induced arthritis.

Journal: Journal of bone and mineral metabolism20050101

Title: Effect of incadronate on corticosteroid-induced osteopenia in rats.

Journal: Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan20040901

Title: Alendronate inhibits urinary calcium microlith formation in a three-dimensional culture model.

Journal: Urological research20040601

Title: Nitrogen-containing bisphosphonates induce S-phase cell cycle arrest and apoptosis of myeloma cells by activating MAPK pathway and inhibiting mevalonate pathway.

Journal: Cellular signalling20030701

Title: Antiinflammatory and chondroprotective effects of the aminobisphosphonate incadronate (YM175) in adjuvant induced arthritis.

Journal: The Journal of rheumatology20030601

Title: [Changes of urinary deoxypyridinoline crosslink/creatinine in rats after ovariectomy and anti-osteoporotic intervention].

Journal: Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae20030601

Title: Incadronate amplifies prostaglandin F2 alpha-induced vascular endothelial growth factor synthesis in osteoblasts. Enhancement of MAPK activity.

Journal: The Journal of biological chemistry20030523

Title: Hydronium (cycloheptylammonio)methylene-1,1-bisphosphonate (hydronium incadronate).

Journal: Acta crystallographica. Section C, Crystal structure communications20030201

Title: Bisphosphonate therapy for hormone refractory prostate cancer with bone metastasis.

Journal: The Journal of urology20030101

Title: Effects of bisphosphonate on bone reaction after placement of titanium implants in tibiae of ovariectomized rats.

Journal: The International journal of oral & maxillofacial implants20030101

Title: Incadronate disodium inhibits advanced glycation end products-induced angiogenesis in vitro.

Journal: Biochemical and biophysical research communications20020920

Title: Comparison of incadronate and alfacalcidol on increased bone turnover caused by ovariectomy in rats.

Journal: European journal of pharmacology20020802

Title: Incadronate and etidronate accelerate phosphate-primed mineralization of MC4 cells via ERK1/2-Cbfa1 signaling pathway in a Ras-independent manner: further involvement of mevalonate-pathway blockade for incadronate.

Journal: Japanese journal of pharmacology20010501

Title: Long-term effect of incadronate disodium (YM-175) on fracture healing of femoral shaft in growing rats.

Journal: Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research20010301

Title: A newly developed bisphosphonate, YM529, is a potent apoptosis inducer of human myeloma cells.

Journal: Leukemia research20010101

Title: [A case of effective bisphosphonate therapy of sequential pamidronate and incadronate for bone metastases from breast cancer].

Journal: Gan to kagaku ryoho. Cancer & chemotherapy20000801

Title: The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway.

Journal: Cancer research19981201

Title: Pharmacokinetics of incadronate, a new bisphosphonate, in healthy volunteers and patients with malignancy-associated hypercalcemia.

Journal: International journal of clinical pharmacology and therapeutics19970601

Building Blocks More >
1384426-12-3
1384426-12-3
(E)-3-(3-Bromo-4,5-dihydroxyphenyl)-n-(3,4,5-trihydroxybenzyl)prop-2-enethioamide
AA00192V | MFCD28127272
13888-03-4
13888-03-4
4-Chloro-2-methylbutyric acid methyl ester
AA0019NZ | MFCD00198001
1391052-00-8
1391052-00-8
1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-δ-hydroxy-5-(1-methylethyl)-β-oxo-3-phenyl-4-[(phenylamino)carbonyl]-, sodium salt (1:1)
AA001A7L
1392804-40-8
1392804-40-8
3-Methoxyazetidine-3-carboxylic acid hydrochloride
AA001ALG | MFCD23106145
139502-01-5
139502-01-5
5-Bromo-2-chloro-4-morpholinopyrimidine
AA001B2M | MFCD03671470
1398534-55-8
1398534-55-8
Carbamic acid, N-[[3-(2H-tetrazol-5-yl)phenyl]methyl]-, 1,1-dimethylethyl ester
AA001BNO | MFCD22423157
1400755-06-7
1400755-06-7
[3-fluoro-5-(tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]methanol
AA001BX9 | MFCD18729955
1404491-67-3
1404491-67-3
Quinoline, 2-(3,5-dimethylphenyl)-5-(2-methylpropyl)-
AA001CD5 | MFCD00002704
14080-50-3
14080-50-3
Thieno[2,3-d]pyrimidin-4-ol
AA001CQ0 | MFCD00706456
1454682-72-4
1454682-72-4
LY3009120
AA001CZ2 | MFCD28411374
Submit
© 2017 AA BLOCKS, INC. All rights reserved.